Generics - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

126 to 150 of 554 results

Australia's 2013-14 Budget includes investment in health services and PBS

14-05-2013

The Australian government today (May 14) presented its Budget for 2013-2014, saying that it delivers…

Asia-PacificFinancialGenericsPharmaceuticalPoliticsPricing

Countries must fix critical access to medicines flaws in Trans-Pacific Trade Pact, says MSF

14-05-2013

As negotiations for the Trans-Pacific Partnership (TPP) restart in Lima, Peru, tomorrow (May 15), countries…

GenericsPatentsPharmaceuticalPoliticsPricing

Brazilian pharma exports to GCC up 73% to reach over $7.4 million in 2012

13-05-2013

Brazil exported $7.48 million worth of pharmaceutical products to the Gulf Cooperation Council (GCC)…

GenericsMarkets & MarketingPharmaceuticalRest of the WorldSouth America

Africa's pharmaceutical industry faces numerous challenges, VoA reports

13-05-2013

Providing Africans with affordable health care could be realized if pharmaceutical products were produced…

Asia-PacificGenericsHealthcarePharmaceuticalProductionRest of the World

Actavis and Warner Chilcott leap on merger talks; possible bid for Adcock Ingram

13-05-2013

US generics major Actavis NYSE: ACT) confirmed on Friday (May 10) that it has entered into early stage…

ActavisAdcock IngramFinancialGenericsMergers & AcquisitionsPharmaceuticalWarner Chilcott

US FDA to allow generic copies of Endo's Opana

13-05-2013

Endo Health Solutions (Nasdaq: ENDP) announced Friday (May 10) that the US Food and Drug Administration…

Endo Health SolutionsEndo PharmaceuticalsGenericsNeurologicalNorth AmericaOpana ERPharmaceuticalRegulation

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData

10-05-2013

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Total real per capita spending on medicines in the USA fell 3.5% in 2012

09-05-2013

Total spending on US medicines fell 3.5 percent on a real per capita basis in 2012 and the use of health…

FinancialGenericsHealthcareNorth AmericaPharmaceutical

Canada strengthens drug safety with GMP now to apply to all APIs

09-05-2013

Canada's Health Minister Leona Aglukkaq this week announced that Canada's Food and Drug Regulations have…

GenericsNorth AmericaPharmaceuticalProductionRegulation

Australia to review way chemotherapy is funded

07-05-2013

Australia's Minister for Health Tanya Plibersek has announced a major review into the way chemotherapy…

Asia-PacificdocetaxelFinancialGenericsHealthcareOncologyPharmaceutical

US FDA warns pregnant women to not use valproate migraine prevention medicines

07-05-2013

The US Food and Drug Administration is alerting health care providers and patients that medications including…

Abbott LaboratoriesGenericsNeurologicalNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationSanofivalproate Sodium Injection

Sagent Pharma to buy remaining 50% stake in Chinese JV for $25 million

06-05-2013

US specialty pharmaceutical company Sagent Pharmaceuticals (Nasdaq: SGNT) has entered into an agreement…

Asia-PacificGenericsKanghong Sagent (Chengdu) PharmaceuticalMergers & AcquisitionsPharmaceuticalProductionSagent Pharmaceuticals

Proposed sourcing on Supreme Court reverse payment drug patent case; lawyers' views

06-05-2013

Within the next several weeks, the US Supreme Court is expected to hand down a ruling in an important…

ActavisGenericsLegalNorth AmericaPatentsPharmaceutical

Teva 1st-qtr sales and profits decline

02-05-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that first-quarter 2013 net revenue dipped…

FinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Arseus/Fagron acquire US pharma compounder Freedom Pharma

01-05-2013

USA-based Freedom Pharmaceuticals says that it has been acquired by Arseus, the holding company for Fagron,…

ArseusFagronFreedom PharmaceuticalsGenericsMergers & AcquisitionsPharmaceutical

Court rules in novel False Claims Act case where one pharma firm sues another viewed by HP&M lawyer

28-04-2013

The US District Court for the Central District of California issued a ruling recently in an unusual,…

AmphastarGenericsLegalLovenoxNorth AmericaPharmaceuticalPricingSanofi

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Argentina's pharma market to almost triple over one decade, says GlobalData

24-04-2013

Argentina's pharmaceutical market is expected to grow from a value of around $5.6 billion in 2012 to…

GenericsMarkets & MarketingPatentsPharmaceuticalProductionRegulationSouth America

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Portugal debt crisis strangling pharma sector growth

21-04-2013

The Portuguese pharmaceutical market has struggled in recent years, and new government policies restraining…

EuropeGenericsMarkets & MarketingPatentsPharmaceuticalPricing

UK's OFT accuses GlaxoSmithKline of "market abuse"

19-04-2013

The UK's Office of Fair Trading (OFT) today (April 19) issued a Statement of Objections to certain pharmaceutical…

AlpharmaEuropeGenericsGlaxoSmithKlineLegalMarkets & MarketingNeurologicalNorton HealthcarePaxilPharmaceuticalPricingSeroxat

126 to 150 of 554 results

Back to top